MA32376B1 - VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME - Google Patents

VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME

Info

Publication number
MA32376B1
MA32376B1 MA33392A MA33392A MA32376B1 MA 32376 B1 MA32376 B1 MA 32376B1 MA 33392 A MA33392 A MA 33392A MA 33392 A MA33392 A MA 33392A MA 32376 B1 MA32376 B1 MA 32376B1
Authority
MA
Morocco
Prior art keywords
leishmaniasis
immunosuppressant
fever
vaccine
longipalpis
Prior art date
Application number
MA33392A
Other languages
Arabic (ar)
English (en)
Inventor
Laurent Bernard Fischer
Jesus G Valenzuela
Original Assignee
Merial Ltd
Gov Of The Usa As Represented By The Secretary Of The Dept Of Health & Humain Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Gov Of The Usa As Represented By The Secretary Of The Dept Of Health & Humain Services filed Critical Merial Ltd
Publication of MA32376B1 publication Critical patent/MA32376B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des vecteurs qui contiennent et expriment in vivo ou in vitro des antigènes salivaires du phlébotome lu. Longipalpis capables de susciter une réponse immunitaire contre la leishmaniose chez l'animal ou l'être humain, des compositions vaccinales comprenant lesdits vecteurs et/ou des polypeptides salivaires de lu. Longipalpis, des procédés de vaccination contre la leishmaniose et des nécessaires à utiliser avec lesdits procédés et compositions.
MA33392A 2008-05-08 2010-12-03 VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME MA32376B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5163508P 2008-05-08 2008-05-08
US10134508P 2008-09-30 2008-09-30
PCT/US2009/042980 WO2009137577A2 (fr) 2008-05-08 2009-05-06 Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome

Publications (1)

Publication Number Publication Date
MA32376B1 true MA32376B1 (fr) 2011-06-01

Family

ID=41110966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33392A MA32376B1 (fr) 2008-05-08 2010-12-03 VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME

Country Status (10)

Country Link
US (2) US8603808B2 (fr)
EP (2) EP2899203B1 (fr)
CN (2) CN103768588A (fr)
AR (1) AR071696A1 (fr)
BR (1) BRPI0915605B8 (fr)
ES (1) ES2760004T3 (fr)
IL (1) IL209107A (fr)
MA (1) MA32376B1 (fr)
MX (2) MX2010012069A (fr)
WO (1) WO2009137577A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012069A (es) * 2008-05-08 2010-12-14 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
EP2890393A2 (fr) 2012-08-30 2015-07-08 Merial, Inc. Dispositif hyperbare et procédés de production de vaccins inactivés et de repliement/solubilisation de protéines recombinantes
WO2014100073A2 (fr) * 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Vecteurs d'expression utilisables en vue de la production de protéines recombinées dans des cellules de mammifère
WO2016073410A1 (fr) 2014-11-03 2016-05-12 Merial, Inc. Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux
UY37753A (es) 2017-06-02 2018-11-30 Amgen Inc Antagonistas de péptido pac1
CN113337542A (zh) * 2021-06-10 2021-09-03 山西大学 高效表达利什曼原虫pepck的人复制缺陷型重组腺病毒载体

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (fr) 1988-11-21 1990-05-21 Franklin Volvovitz Cutireaction et trousse pour le depistage du sida
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
EP0803573A1 (fr) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Construction pour l'expression polycistronique contenant des cytokines pour des vaccins multivalents
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
EP0979101B1 (fr) 1996-07-03 2010-10-27 Merial, Inc. ADENOVIRUS CANIN 2 RECOMBINANT (ACR2) CONTENANT DE l'ADN EXOGENE
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1203819A3 (fr) 2000-10-06 2002-08-07 Transgene S.A. Vecteurs anti-inflammatoires
US7388089B2 (en) * 2001-06-19 2008-06-17 The United States Of America As Represented By The Department Of Health And Human Services Anti-arthropod vector vaccines method of selecting and uses thereof
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US7078507B2 (en) 2001-11-09 2006-07-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Synthetic genes for malarial proteins and methods of use
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
ES2447843T3 (es) * 2002-10-29 2014-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polip�ptidos de Lutzomyia longipalpis y m�todos de uso
EP1615663B1 (fr) * 2003-10-24 2007-12-26 Mologen AG Produit de traitement des infections par leishmania
CA2570156C (fr) 2004-06-04 2014-09-30 Merial Limited Administration sans aiguille d'un vaccin contre le felv
US7512883B2 (en) * 2004-06-30 2009-03-31 Microsoft Corporation Portable solution for automatic camera management
CA2540736A1 (fr) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides de leishmania major et polynucleotides les encodant, applications vaccinales, therapeutiques et diagnostiques de ceux-ci
US7794736B2 (en) * 2006-11-21 2010-09-14 Merial Limited Canine Leishmania vaccine
WO2009017689A2 (fr) * 2007-08-02 2009-02-05 Government Of The U. S. A., As Represented By The Secretary, Dept. Of Health And Human Services Procédés de détection et de prévention d'une infestation de tiques et d'une transmission de pathogènes
MX2010012069A (es) * 2008-05-08 2010-12-14 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
BRPI0912768A2 (pt) * 2008-05-21 2016-05-17 Infectious Disease Res Inst vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose
WO2010078469A2 (fr) * 2008-12-31 2010-07-08 The Usa As Represented By The Secretary, Department Of Health And Human Services Protéines salivaires de phlébotome en tant que nouveaux inhibiteurs du facteur xa et procédés d'utilisation
WO2010078466A2 (fr) * 2008-12-31 2010-07-08 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Protéines salivaires de phlébotome avec une activité anticomplément et leurs procédés d'utilisation
WO2012138377A2 (fr) * 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania Utilisation de vecteurs de vaccin de listeria pour renverser l'insensibilité au vaccin chez des individus infectés par des parasites
BR112013012482A8 (pt) * 2010-11-18 2017-07-11 Merial Ltd Modelo de desafio para leishmaniose canina por picadas de mosquito-palha
US9926349B2 (en) * 2011-07-21 2018-03-27 Consejo Superior De Investigaciones Cientifícas (Csic) Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes
ES2711878T3 (es) * 2012-03-20 2019-05-08 Merial Inc Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma

Also Published As

Publication number Publication date
US20090324649A1 (en) 2009-12-31
BRPI0915605B8 (pt) 2021-09-08
US9228002B2 (en) 2016-01-05
CN103768588A (zh) 2014-05-07
US8603808B2 (en) 2013-12-10
EP2283035B1 (fr) 2015-07-29
IL209107A (en) 2017-08-31
WO2009137577A2 (fr) 2009-11-12
EP2899203B1 (fr) 2019-07-10
IL209107A0 (en) 2011-01-31
MX348137B (es) 2017-05-29
US20140294875A1 (en) 2014-10-02
EP2899203A2 (fr) 2015-07-29
MX2010012069A (es) 2010-12-14
EP2899203A3 (fr) 2015-08-05
BRPI0915605A2 (pt) 2016-02-02
CN102066411A (zh) 2011-05-18
HK1150616A1 (zh) 2012-01-06
BRPI0915605B1 (pt) 2021-08-24
EP2283035A2 (fr) 2011-02-16
WO2009137577A3 (fr) 2010-03-25
AR071696A1 (es) 2010-07-07
ES2760004T3 (es) 2020-05-12

Similar Documents

Publication Publication Date Title
EA201070329A1 (ru) Векторы и конструкции для доставки гриппозного антигена
WO2005099752A3 (fr) Vecteurs et constructions d'administration d'antigenes
EP2517557A3 (fr) Modèles animaux et molécules thérapeutiques
MY154956A (en) Chimeric adenoviral vectors
MA32376B1 (fr) VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME
GT201200189A (es) Antagonistas de pcsk9
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
GT200800132A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
WO2009133378A3 (fr) Produits et procédés permettant de stimuler une réponse immunitaire
EA200701362A1 (ru) Агонисты glp-1, композиции, способы и применения
TR201000668T1 (tr) Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
EA201100674A1 (ru) Вакцина против вируса африканской чумы лошадей
WO2012135701A3 (fr) Compositions et procédés pour la détection d'anaplasma platys
EP2473051A4 (fr) Nouvelles compositions et procédés de préparation de 5-amino ou amino substitué 1,2,3-triazoles et de formulations d'orotate de triazole
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
WO2008103819A3 (fr) Pseudo-particules virales (vlp) chimériques de la maladie de newcastle
MA31014B1 (fr) Vaccin contre la leishmania canine.
IN2014CN00547A (fr)
MX361804B (es) Vacunas genéticas contra el virus hendra y el virus nipah.
WO2006117538A3 (fr) Dosages et leur utilisation
NO20075272L (no) Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser
HK1144153B (en) Influenza antigen delivery vectors and constructs
TN2010000500A1 (en) Leishmania vaccine using sand fly salivary immunogen